Last updated: August 13, 2026
Cosmo Technologies Limited v. Actavis Laboratories FL Inc., No. 1:15-cv-00164-LPS, was a Hatch-Waxman patent case concerning Actavis' abbreviated new drug application for a generic version of Uceris, an extended-release budesonide tablet marketed by Salix Pharmaceuticals. The dispute centered on Cosmo's controlled-release formulation patent, U.S. Patent No. 8,865,688. The Federal Circuit addressed the meaning of the patent's "inner matrix" and "outer matrix" limitations and affirmed the district court's noninfringement judgment in favor of Actavis. Cosmo Technologies Ltd. v. Actavis Laboratories FL, Inc., 881 F.3d 1373 (Fed. Cir. 2018).
What drug and patents were involved in Cosmo Technologies v. Actavis?
The litigation involved Uceris, also known as budesonide extended-release tablets.
| Item |
Details |
| Reference product |
Uceris extended-release tablets |
| Active ingredient |
Budesonide |
| Therapeutic category |
Corticosteroid for induction of remission in ulcerative colitis |
| Reference sponsor |
Salix Pharmaceuticals, Ltd., later associated with Bausch Health |
| Patent holder/plaintiff |
Cosmo Technologies Limited |
| Generic applicant |
Actavis Laboratories FL Inc. |
| Court |
U.S. District Court for the District of Delaware |
| Civil action |
No. 1:15-cv-00164-LPS |
| District judge |
Leonard P. Stark |
| Federal Circuit citation |
881 F.3d 1373 |
| ANDA pathway |
Section 505(j) of the Federal Food, Drug, and Cosmetic Act |
| Core patent |
U.S. Patent No. 8,865,688 |
Cosmo asserted the '688 patent against Actavis after receiving notice of Actavis' ANDA and Paragraph IV certification. The asserted patent covered controlled-release oral pharmaceutical compositions designed to deliver budesonide to the lower gastrointestinal tract.
What did U.S. Patent No. 8,865,688 protect?
The '688 patent claimed a multilayer or matrix-based oral dosage form containing budesonide. The formulation was intended to limit release in the stomach and small intestine and provide release in the colon or lower intestinal tract.
The disputed claim architecture included:
- An inner matrix containing the active pharmaceutical ingredient;
- An outer matrix surrounding or associated with the inner matrix;
- Hydrophilic and lipophilic components;
- Controlled release characteristics;
- Budesonide as the therapeutic agent.
The patent's commercial value came from its formulation protection. The claims did not merely cover budesonide as a molecule. Budesonide had long been known, and the patent estate focused on the delivery system, release profile, and matrix structure.
What formulation limitations were disputed?
The principal dispute concerned the construction and application of "inner matrix" and "outer matrix."
Cosmo argued that Actavis' proposed generic product contained the claimed matrix arrangement. Actavis argued that its formulation did not satisfy the required spatial and structural relationship between the inner and outer matrices.
The Federal Circuit treated the claim language and specification as requiring a meaningful distinction between the two matrices. The court rejected an interpretation that would allow the limitations to be satisfied merely because the product contained the same ingredients or exhibited similar release behavior.
What was the procedural history of the case?
When was the case filed?
Cosmo filed the action in the District of Delaware in 2015 after Actavis submitted an ANDA seeking approval to market generic budesonide extended-release tablets.
The filing of a patent infringement action based on a Paragraph IV certification triggered the Hatch-Waxman stay of FDA approval for up to 30 months, subject to statutory exceptions and court developments.
What did the district court decide?
The district court construed the disputed formulation terms and entered judgment for Actavis on noninfringement. The court concluded that Actavis' proposed product did not meet the required "inner matrix" and "outer matrix" limitations of the asserted claims.
Cosmo appealed the claim construction and noninfringement ruling to the U.S. Court of Appeals for the Federal Circuit.
What did the Federal Circuit decide?
On February 9, 2018, the Federal Circuit affirmed the district court's judgment. The appellate court held that the asserted claims required the claimed matrix arrangement and that Actavis' proposed formulation did not infringe under the proper construction of the patent claims. Cosmo Technologies, 881 F.3d at 1373.
The decision left Actavis with a noninfringement judgment for the product described in its ANDA.
What was the key legal issue in the Federal Circuit appeal?
The central issue was claim construction, not the validity of the '688 patent.
The Federal Circuit examined whether the patent required:
- A separately identifiable inner matrix;
- An outer matrix positioned around or outside the inner matrix;
- The claimed relationship to exist in the finished dosage form;
- More than a functional or ingredient-based overlap between the two matrices.
The court relied on the intrinsic evidence, including the claim language, specification, and prosecution history. The decision illustrates the risk of drafting formulation claims with structural terms that may be construed narrowly during ANDA litigation.
The outcome was commercially important because a generic applicant can avoid infringement by modifying the structure of the dosage form, even when the proposed product has the same active ingredient, therapeutic use, and general release objective.
Did Actavis win a Paragraph IV challenge?
Yes. Actavis prevailed on the asserted patent through a noninfringement judgment.
The case did not establish that the '688 patent was invalid. The decision rested on the conclusion that Actavis' proposed product did not satisfy the asserted claim limitations. That distinction matters for future challengers. A noninfringement judgment based on a specific ANDA formulation may not eliminate the patent's enforceability against other products with materially different designs.
Was the case a judgment of invalidity?
No. The Federal Circuit's ruling was a noninfringement decision. The '688 patent was not held invalid in the reported appellate decision.
Did the ruling authorize immediate generic launch?
The reported Federal Circuit decision resolved the infringement dispute in Actavis' favor, but FDA approval and commercial launch remained separate regulatory and commercial questions. The FDA could approve an ANDA only after satisfying applicable approval requirements and resolving any statutory approval bar or exclusivity period.
What was the Orange Book status of Uceris?
Uceris was listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The relevant listings included formulation and method-of-use patents associated with budesonide extended-release tablets.
The Orange Book functioned as the basis for the ANDA applicant's patent certifications. A Paragraph IV certification asserted that the listed patent was invalid, unenforceable, or would not be infringed by the proposed generic product.
Orange Book listing status should be separated from ultimate litigation outcome:
- A listed patent can remain in force after a defendant wins a particular infringement case.
- A noninfringement judgment may be product-specific.
- The same patent can produce different outcomes against different ANDA formulations.
- FDA approval timing depends on patent litigation, regulatory exclusivity, settlement terms, and statutory stays.
What other patents protected Uceris?
The Uceris patent estate included patents directed to controlled-release budesonide compositions and related pharmaceutical technology. Public patent records identify U.S. Patent No. 8,865,688 as the principal patent involved in this action. Later-issued patents and related family members may have covered overlapping release technology, but the reported Federal Circuit appeal was focused on the '688 patent.
Patent-family analysis is important because a generic applicant can defeat one formulation patent while remaining exposed to:
- Continuation patents;
- Later-issued formulation claims;
- Method-of-use claims;
- Manufacturing-process patents;
- Patent claims covering alternative dosage forms;
- Regulatory exclusivity independent of patent term.
How strong was Cosmo's patent position?
The Cosmo estate had meaningful commercial value but demonstrated claim-construction risk.
Strengths
- The patent targeted a differentiated delivery system rather than an old active ingredient.
- The claims were linked to a specific release architecture.
- Uceris had an FDA-approved indication and an established commercial market.
- Formulation patents can create substantial barriers when the reference product's performance depends on the protected structure.
Weaknesses
- The asserted structural terms were susceptible to a narrow construction.
- A generic applicant could design around the claimed matrix relationship.
- Similar pharmacokinetic or dissolution performance did not necessarily establish infringement.
- The noninfringement judgment reduced the patent's leverage against the specific Actavis ANDA.
The litigation shows that formulation patents should be evaluated at the level of the actual ANDA composition, not by comparing only active ingredient, dosage strength, indication, or clinical effect.
What was the generic-entry risk after the Actavis decision?
The decision increased generic-entry risk for Uceris because Actavis obtained a favorable infringement judgment on the principal patent at issue. The impact was narrower than a declaration that the entire Uceris patent estate was invalid.
Generic-entry analysis required evaluation of:
| Risk factor |
Effect on Uceris exposure |
| Actavis noninfringement judgment |
Reduced barrier for Actavis' specific ANDA product |
| Remaining Orange Book patents |
Could delay or complicate approval |
| Patent expiration |
Created a hard endpoint for patent-based exclusivity |
| Formulation design-around |
Increased the likelihood of noninfringing alternatives |
| Method-of-use claims |
Could preserve narrower enforcement rights |
| Regulatory exclusivity |
Could delay approval despite a favorable patent result |
| Commercial substitution |
Depended on FDA approval, labeling, supply, and payer access |
The ruling did not create biosimilar risk. Uceris is a small-molecule budesonide product, not a biologic. The relevant competitive threat was generic substitution under the ANDA pathway.
Were there licensing deals or settlement agreements?
The reported appellate decision does not establish a material license or commercial settlement as the basis for case resolution. The public litigation record is best characterized by the district court's noninfringement judgment and the Federal Circuit's affirmance.
A separate settlement agreement, if any, would need to be evaluated through court docket filings, FTC settlement materials, or later regulatory records. The appellate ruling itself does not report a reverse-payment settlement that replaced the merits judgment.
What litigation affects the Uceris competitive landscape?
The Cosmo-Actavis action was significant because it tested the enforceability of the Uceris formulation patent against a specific ANDA product. Its practical effect was to clarify that:
- Formulation claims are construed according to their structural limitations.
- A generic can avoid infringement through a product architecture that does not contain the required matrix relationship.
- Similar dissolution or therapeutic performance does not automatically satisfy structural claim language.
- A patent holder must prove infringement by the ANDA product, not by the reference product's commercial characteristics.
The decision also provided a design-around pathway for future generic applicants. Companies developing generic budesonide extended-release tablets would likely focus on alternative matrix arrangements, coating systems, release-control polymers, or manufacturing sequences.
What are the geographic and manufacturing implications?
The case was a U.S. patent action. Its judgment did not determine patent rights in Europe, Canada, Japan, or other jurisdictions.
Cosmo's underlying technology had international relevance because controlled-release budesonide formulations may be protected through corresponding foreign patent families. The geographic risk profile depends on:
- National patent grants;
- Local claim scope;
- Patent-term adjustments;
- Supplementary protection certificates in Europe;
- National Orange Book equivalents;
- Local regulatory exclusivity;
- Manufacturing-site and process claims.
Manufacturing barriers can remain important even where product claims are avoided. A generic developer may need to qualify alternative excipients, compression processes, coating conditions, dissolution specifications, and stability data. Those technical changes can increase development cost without restoring the patent holder's exclusivity.
Key Takeaways
- The case concerned Actavis' ANDA for generic Uceris, an extended-release budesonide tablet.
- Cosmo asserted U.S. Patent No. 8,865,688.
- The principal dispute involved the patent's "inner matrix" and "outer matrix" limitations.
- The district court entered judgment of noninfringement for Actavis.
- The Federal Circuit affirmed in 2018.
- The patent was not held invalid in the reported appellate decision.
- The ruling reduced Cosmo's leverage against Actavis' specific ANDA product.
- The decision did not eliminate every patent or regulatory barrier associated with Uceris.
- Biosimilar risk was not relevant because budesonide is a small-molecule drug.
- The case demonstrates the importance of structural claim drafting and ANDA-specific infringement analysis.
FAQs About Cosmo Technologies v. Actavis
Did Cosmo lose the entire Uceris patent estate?
No. Cosmo lost the reported infringement dispute involving the asserted claims of the '688 patent against Actavis' ANDA product. The decision did not invalidate every Uceris-related patent.
Was Actavis' generic Uceris product found to infringe?
No. The Federal Circuit affirmed that Actavis' proposed product did not infringe the asserted claims under the applicable claim construction.
Did the court invalidate U.S. Patent No. 8,865,688?
No. The appellate outcome was based on noninfringement, not invalidity.
Does the decision apply to all generic budesonide extended-release products?
No. The judgment was tied to the product described in Actavis' ANDA. Another generic product with a different formulation could present a different infringement analysis.
Why are matrix limitations important in controlled-release drug patents?
Matrix limitations define how the active ingredient is embedded and released in the dosage form. They can distinguish a patented delivery system from unprotected alternatives, but narrow structural language also creates opportunities for design-around products.
References
-
Cosmo Technologies Ltd. v. Actavis Laboratories FL, Inc., 881 F.3d 1373 (Fed. Cir. 2018).
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Patent No. 8,865,688. (2014). Controlled release pharmaceutical compositions. U.S. Patent and Trademark Office.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. FDA.
